Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Viral Conjunctivitis Overview 6 Therapeutics Development 7 Pipeline Products for Viral Conjunctivitis - Overview 7 Viral Conjunctivitis - Therapeutics under Development by Companies 8 Viral Conjunctivitis - Pipeline Products Glance 9 Clinical Stage Products 9 Early Stage Products 10 Viral Conjunctivitis - Products under Development by Companies 11 Viral Conjunctivitis - Companies Involved in Therapeutics Development 12 Adenovir Pharma AB 12 NanoViricides, Inc. 13 Panoptes Pharma Ges.m.b.H. 14 Shire Plc 15 Starpharma Holdings Limited 16 Viral Conjunctivitis - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 25 APD-209 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 APD-514 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 astodrimer - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 EKCCide-I - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 PP-001 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 SHP-640 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Viral Conjunctivitis - Dormant Projects 36 Viral Conjunctivitis - Discontinued Products 37 Viral Conjunctivitis - Product Development Milestones 38 Featured News & Press Releases 38 May 13, 2013: Starpharma's Dendrimer SPL7013 Demonstrates Potential As Viral Conjunctivitis Treatment 38 Oct 11, 2012: Adenovir Pharma Announces Completion Of Phase I Study Of APD -209 To Treat Epidemic Keratoconjunctivitis 38 Aug 22, 2011: Researchers Discover New Drug To Treat Epidemic Keratoconjuntivitis 39 May 05, 2010: Foresight Biotherapeutics, Inc 's Drug FST-100 Reduces Infectious Adenoviral Titers And Improves Clinical Signs in Conjunctivitis Model 39 Appendix 41 Methodology 41 Coverage 41 Secondary Research 41 Primary Research 41 Expert Panel Validation 41 Contact Us 41 Disclaimer 42

List of Tables Number of Products under Development for Viral Conjunctivitis, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Clinical Stage Development, H2 2016 9 Comparative Analysis by Early Stage Development, H2 2016 10 Products under Development by Companies, H2 2016 11 Viral Conjunctivitis - Pipeline by Adenovir Pharma AB, H2 2016 12 Viral Conjunctivitis - Pipeline by NanoViricides, Inc., H2 2016 13 Viral Conjunctivitis - Pipeline by Panoptes Pharma Ges.m.b.H., H2 2016 14 Viral Conjunctivitis - Pipeline by Shire Plc, H2 2016 15 Viral Conjunctivitis - Pipeline by Starpharma Holdings Limited, H2 2016 16 Assessment by Monotherapy Products, H2 2016 17 Number of Products by Stage and Target, H2 2016 19 Number of Products by Stage and Mechanism of Action, H2 2016 21 Number of Products by Stage and Route of Administration, H2 2016 23 Number of Products by Stage and Molecule Type, H2 2016 24 Viral Conjunctivitis - Dormant Projects, H2 2016 36 Viral Conjunctivitis - Discontinued Products, H2 2016 37 List of Figures Number of Products under Development for Viral Conjunctivitis, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Assessment by Monotherapy Products, H2 2016 17 Number of Products by Top 10 Targets, H2 2016 18 Number of Products by Stage and Top 10 Targets, H2 2016 18 Number of Products by Mechanism of Actions, H2 2016 20 Number of Products by Stage and Mechanism of Actions, H2 2016 20 Number of Products by Routes of Administration, H2 2016 22 Number of Products by Stage and Routes of Administration, H2 2016 22 Number of Products by Stage and Molecule Types, H2 2016 24

Adenovir Pharma AB NanoViricides, Inc. Panoptes Pharma Ges.m.b.H. Shire Plc Starpharma Holdings Limited